Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a.

Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin L, Cazzato G.

J Neurol Sci. 2003 Dec 15;216(1):113-8.

PMID:
14607312
2.

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators.

Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908X280545 . Epub 2008 Feb 29.

PMID:
18315940
3.

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.

Herndon RM, Rudick RA, Munschauer FE 3rd, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.

Mult Scler. 2005 Aug;11(4):409-19.

PMID:
16042223
4.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
5.

Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a.

Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G; Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients study group.

J Neurol. 2010 Apr;257(4):584-9. doi: 10.1007/s00415-009-5378-x. Epub 2009 Nov 18.

PMID:
19921303
6.

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.

Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S; European Interferon Beta-1a IM Dose-Comparison Study Investigators.

Neurology. 2005 Jul 12;65(1):40-7.

PMID:
16009883
7.

Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.

Clanet M, Kappos L, Hartung HP, Hohlfeld R; European IFNbeta-1a Dose-Comparison Study Investigators.

Mult Scler. 2004 Apr;10(2):139-44.

PMID:
15124757
8.

[Quality of life in patients with remitting-relapsing multiple sclerosis in Germany].

Haupts M, Elias G, Hardt C, Langenbahn H, Obert H, Pöhlau D, Sczesni B, von Wussow P.

Nervenarzt. 2003 Feb;74(2):144-50. German.

PMID:
12596015
9.

Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.

Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T.

Mult Scler. 2002 Oct;8(5):377-81.

PMID:
12356203
10.

Quality of life during the first 6 months of interferon-beta treatment in patients with MS.

Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH.

Mult Scler. 2000 Oct;6(5):338-42.

PMID:
11064444
11.

Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.

Mohr DC, Likosky W, Dwyer P, Van Der Wende J, Boudewyn AC, Goodkin DE.

Arch Neurol. 1999 Oct;56(10):1263-5.

PMID:
10520943
12.

Treatment with interferon beta-1b improves quality of life in multiple sclerosis.

Rice GP, Oger J, Duquette P, Francis GS, Bélanger M, Laplante S, Grenier JF.

Can J Neurol Sci. 1999 Nov;26(4):276-82.

PMID:
10563212
13.

Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study.

Miller DM, Cohen JA, Kooijmans M, Tsao E, Cutter G, Baier M.

Mult Scler. 2006 Apr;12(2):180-6.

PMID:
16629421
14.

Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.

Miller DM, Weinstock-Guttman B, Bourdette D, You X, Foulds P, Rudick RA.

Mult Scler. 2011 Jun;17(6):734-42. doi: 10.1177/1352458510397221. Epub 2011 Feb 7.

PMID:
21300736
15.

Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.

Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C; COGIMUS Study Group.

Mult Scler. 2011 Aug;17(8):991-1001. doi: 10.1177/1352458511401943. Epub 2011 Apr 18.

PMID:
21502310
16.

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.

Mult Scler. 2009 Aug;15(8):965-76. doi: 10.1177/1352458509105229. Epub 2009 May 22.

PMID:
19465443
17.
18.

Quality of life in patients with multiple sclerosis: the impact of fatigue and depression.

Janardhan V, Bakshi R.

J Neurol Sci. 2002 Dec 15;205(1):51-8.

PMID:
12409184
19.

Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects.

Gottberg K, Gardulf A, Fredrikson S.

Mult Scler. 2000 Oct;6(5):349-54.

PMID:
11064446
20.

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.

Neurology. 2006 Sep 26;67(6):944-53.

PMID:
17000959
Items per page

Supplemental Content

Write to the Help Desk